### At a GlanceVertex reported strong Q2 2026 results, with management stating total revenue grew 12% year-over-year, driven primarily by the CF product portfolio and new drugs CASGEVY and JOURNAVX. The company announced the acquisition of Crinetics Pharmaceuticals, establishing a fifth business pillar (rare endocrine diseases), and raised its full-year revenue guidance.
Key Data: Total revenue of $3.3 billion (+12% YoY), global CF revenue +11% YoY, non-CF products CASGEVY and JOURNAVX combined contributed $126 million (CASGEVY $76 million, JOURNAVX $50 million).
Business Progress: In CF, ALYFTREK generated over $1 billion in H1 revenue, becoming a new standard of care, with over two-thirds of younger patients achieving sweat chloride levels at carrier level (<30 mmol/L). CASGEVY received FDA approval for children aged 2-11, with Q2 revenue up approximately 75% sequentially, and H1 infusion volumes exceeding the full year 2025 total. JOURNAVX prescriptions reached approximately 535,000 in Q2, up about 45% sequentially, covering 260 million lives (180 million of which are unrestricted). In the renal pipeline, the BLA for Pove (IgAN) was accepted by the FDA with a PDUFA date of November 30; the AMPLITUDE study for inaxaplin (AMKD) is expected to complete enrollment by year-end, with an interim analysis in early 2027. In T1D, the IND for VX-017 (O-type blood islet cells) was cleared, with Phase I/II studies set to begin.
Guidance & Outlook: Raised full-year 2026 revenue guidance to $13.1-13.2 billion (previously unspecified), maintaining the non-CF product revenue target of ≥$500 million. Non-GAAP operating expense guidance remains at $5.65-5.75 billion, expected to be at the high end of the range. The Crinetics acquisition is expected to close in Q3, becoming accretive to non-GAAP operating profit by 2029.
Risk/Highlight Signals: Management emphasized that JOURNAVX prescription growth exceeded expectations, but increased use of PSP programs is expected to normalize Gross-to-Net in the first half of 2027. In CF, next-generation drugs (e.g., VX-828) will only advance assets that can surpass ALYFTREK. The Crinetics acquisition's PALSONIFY and Atumelnant have a combined peak sales opportunity of approximately $5 billion.